Clinical Trial

Efficacy of Pediococcus Acidilactici as add-on to Antipsychotic Drugs on Metabolic Syndrome Disturbances in First-episode Psychosis and Schizophrenia Spectrum Disorders.

Study acronym: GLUCOPSICO
Completed
View on ClinicalTrials.gov →
Summary
The aim of the present study is to evaluate the effectiveness of the addition of the postbiotic Pediococcus acidilactici (pA1c®HI) on amelioration of metabolic disturbances in patients with (FEP) or (SSD) treated with antipsychotic drugs.
Protocol Amendment History 1 change
critical Trial completed 2026-04-17
Trial Details
NCT Number NCT07371325
Lead Sponsor Manuel Jesús Cuesta Zurita
Collaborators: GENBIOMA Aplicaciones SL, Universidad Pública de Navarra
Conditions SCHIZOPHRENIA 1 (Disorder), Metabolic Abnormalities, Postbiotic Supplement
Enrollment 36 participants
Start Date 2024-09-08
Primary Completion 2026-01-23 (estimated)
Study Completion 2026-01-23 (estimated)
Updated on ClinicalTrials.gov 2026-04-16